4//SEC Filing
RespireRx Pharmaceuticals Inc. 4
Accession 0001363763-17-000007
CIK 0000849636operating
Filed
Jan 19, 7:00 PM ET
Accepted
Jan 20, 9:43 PM ET
Size
10.4 KB
Accession
0001363763-17-000007
Insider Transaction Report
Form 4
Purcell Richard David Jr.
SVP - Research & Development
Transactions
- Award
Common Stock Options (to purchase shares of Common Stock)
2017-01-18+40,000→ 40,000 totalExercise: $3.90Exp: 2022-01-18→ Common Stock (40,000 underlying)
Holdings
- 61,539
Common Stock Options (to purchase shares of Common Stock)
Exercise: $7.38Exp: 2021-03-31→ Common Stock (61,539 underlying) - 6,154
Common Stock Options (to purchase shares of Common Stock)
Exercise: $8.13Exp: 2022-06-30→ Common Stock (6,154 underlying) - 9,231
Common Stock Options (to purchase shares of Common Stock)
Exercise: $6.40Exp: 2022-08-18→ Common Stock (9,231 underlying)
Footnotes (5)
- [F1]These Common Stock Options vest in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017.
- [F2]The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.
- [F3]These Common Stock Options vested in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016.
- [F4]These Common Stock Options vested in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016.
- [F5]The Common Stock Options vested in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015.
Documents
Issuer
RespireRx Pharmaceuticals Inc.
CIK 0000849636
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000849636
Filing Metadata
- Form type
- 4
- Filed
- Jan 19, 7:00 PM ET
- Accepted
- Jan 20, 9:43 PM ET
- Size
- 10.4 KB